Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
SØREN BREGENHOLT Corporate Vice President Denmark BARBARA ARANEO Innovation Sourcing Director USA MARTIN E. JUDGE Innovation Sourcing Directorr Denmark CHUCK GRAY Innovation Sourcing Director USA ANAND GAUTAM Innovation Sourcing Director Denmark ANAND GAUTAM Innovation scouting director Denmark IN PROTEIN-BASED THERAPEUTICS AND TECHNOLOGIES TOMAS LANDH Senior Principal Scientist Denmark JØRN ROLAND MÜLLER Innovation Sourcing Director Denmark Partnering for innovation Novo Nordisk is seeking potential partners who can help us to improve patient therapy by discovering innovative peptide- and protein-based therapeutics for treatment of • DIABETES • OBESITY • DIABETIC LATE COMPLICATIONS • PROTEIN TECHNOLOGIES • HAEMOPHILIA Discover more about Partnering for innovation at http://www.novonordisk.com/rnd/partnering MARTIN [email protected] +45 30797988 CHUCK [email protected] +1 8453237463 TOMAS [email protected] +45 30757115 ANAND [email protected] +45 30797971 Looking for Diabetes JØRN [email protected] +45 30751988 For more information about Novo Nordisk, visit novonordisk.com Or follow us on BARBARA [email protected] +1 2064738289 Insulin and GLP-1 receptor peptide-agonists: • Insulins and GLP-1s with novel therapeutic properties o Optimised for oral delivery o Modified duration of action o Improved side-effect profile Therapeutic proteins and peptides affecting: • Glucose regulation o With anti-obesity effects, and/or anti-hyperlipidaemia, and/or anti-atherosclerotic effects o Without inducing hypoglycaemia, and/or inducing weight gain • Insulin secretion • Insulin resistance • Beta-cell mass • Inflammation related to diabetes and obesity • Prevention/progression of diabetes Obesity Protein peptides for obesity treatment: • Addressing comorbidities • Affecting e.g. o Appetite regulation o Energy expenditure Haemophilia • Longer duration of action of coagulation factors • Novel bypassing principles • Tolerance and immunogenicity • Joint health Human growth hormone disorders • Longer duration of action of hGH • Oral delivery Diabetic late complications o o • Novel biologics to treat microvascular complications: o Diabetic retinopathy o Diabetic nephropathy New protein delivery devices • Injection of soluble protein formulations • Reconstitution and infusion of lyophilised protein formulations Protein technologies Protein and peptide technologies: • Expression • Modification • Production Formulation and delivery technologies: • Liquid • Oral • Sustained/triggered release